Document Classification

Section Type: RESULTS

Text: However, compared with placebo, candesartan significantly reduced plasma levels of malondialdehyde from 1. 50 + / - 0. 07 to 1. 29 + / - 0. 09 microM (p = 0. 009) ; improved the percent flow-mediated dilator response to hyperemia from 5. 17 + / - 0. 24 to 6. 22 + / - 0. 26 % (p < 0. 001) ; and, furthermore, reduced plasma levels of monocyte chemoattractant protein (MCP-1) from 213 + / - 8 to 190 + / - 7 pg/ml (p = 0. 003), tumor necrosis factor-alpha from 2. 93 to 2. 22 pg/ml (p = 0. 026), and plasminogen activator inhibitor type 1 from 74 + / - 4 to 53 + / - 4 ng/ml (p < 0. 001) but not C-reactive protein (CRP), matrix metalloproteinase protein, and fibrinogen.